Romosozumab: Additional Phase III data

Additional data from the open-label, international Phase III STRUCTURE trial in 436 postmenopausal women with osteoporosis at high risk for fracture who were previously treated with bisphosphonate therapy showed that once-monthly 210

Read the full 320 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE